Neuropeptides in Alzheimer's disease. Clinical implications.
Since the isolation and sequencing of the enkephalins in the mid-1970s, there has been an explosion of knowledge concerning putative peptide neurotransmitters in the brain. This article focuses on selected developments in neuropeptide research that may have bearing on our understanding of and clinical approach to the dementing degenerative disorder Alzheimer's disease (AD), a cardinal feature of which is impairment of memory.
D000324:Adrenocorticotropic Hormone / Q000502:physiology; D000544:Alzheimer Disease / Q000378:metabolism / Q000503:physiopathology*; D001127:Arginine Vasopressin / Q000502:physiology; D001921:Brain / Q000378:metabolism / Q000503:physiopathology*; D004723:Endorphins / Q000502:physiology; D006801:Humans; D008568:Memory / Q000502:physiology; D009479:Neuropeptides / Q000378:metabolism* / Q000502:physiology; D010121:Oxytocin / Q000502:physiology
D004723:Endorphins; D009479:Neuropeptides; D001127:Arginine Vasopressin; D010121:Oxytocin; D000324:Adrenocorticotropic Hormone